Changes in Body Adiposity, Dietary Intake, Physical Activity and Quality of Life of Obese Individuals Submitted to Intragastric Balloon Therapy for 6 Months.


Journal

Obesity surgery
ISSN: 1708-0428
Titre abrégé: Obes Surg
Pays: United States
ID NLM: 9106714

Informations de publication

Date de publication:
03 2019
Historique:
pubmed: 12 12 2018
medline: 20 3 2020
entrez: 12 12 2018
Statut: ppublish

Résumé

Obesity is an important risk factor for several chronic diseases and also is associated with worse quality of life. Intragastric balloon (IGB) is an effective method for weight loss. Although changes in lifestyle are critical to weight loss during and after IGB therapy, only a few studies evaluated dietary intake and none evaluated changes in physical activity with a validated questionnaire during the treatment. The aim of this study was to evaluate changes in total and central body adiposity, dietary intake, physical activity, and quality of life of patients with obesity submitted to IGB treatment for 6 months. Prospective observational study involving 42 patients with obesity using IGB for 6 months. The patients were evaluated, on the day of insertion and withdrawal or adjustment of IGB for total and central body adiposity (anthropometry and bioelectrical impedance), dietary intake, physical activity (Baecke questionnaire), and quality of life (SF-36 questionnaire). There was a significant decrease in total and central body adiposity. The mean % total weight loss and % excess weight loss were 15.88 ± 1.42 and 56.04 ± 4.90, respectively and waist circumference decreased 13.33 ± 1.39 cm. There was a reduction in energy intake, an increase in physical activity, and an improvement of quality of life during IGB treatment. The present study suggests that IGB treatment during 6 months in individuals with obesity is effective for decreasing total and central body adiposity being associated with reduction in energy intake, increase in physical activity, and improvement in quality of life.

Sections du résumé

BACKGROUND
Obesity is an important risk factor for several chronic diseases and also is associated with worse quality of life. Intragastric balloon (IGB) is an effective method for weight loss. Although changes in lifestyle are critical to weight loss during and after IGB therapy, only a few studies evaluated dietary intake and none evaluated changes in physical activity with a validated questionnaire during the treatment. The aim of this study was to evaluate changes in total and central body adiposity, dietary intake, physical activity, and quality of life of patients with obesity submitted to IGB treatment for 6 months.
METHODS
Prospective observational study involving 42 patients with obesity using IGB for 6 months. The patients were evaluated, on the day of insertion and withdrawal or adjustment of IGB for total and central body adiposity (anthropometry and bioelectrical impedance), dietary intake, physical activity (Baecke questionnaire), and quality of life (SF-36 questionnaire).
RESULTS
There was a significant decrease in total and central body adiposity. The mean % total weight loss and % excess weight loss were 15.88 ± 1.42 and 56.04 ± 4.90, respectively and waist circumference decreased 13.33 ± 1.39 cm. There was a reduction in energy intake, an increase in physical activity, and an improvement of quality of life during IGB treatment.
CONCLUSION
The present study suggests that IGB treatment during 6 months in individuals with obesity is effective for decreasing total and central body adiposity being associated with reduction in energy intake, increase in physical activity, and improvement in quality of life.

Identifiants

pubmed: 30536199
doi: 10.1007/s11695-018-3609-x
pii: 10.1007/s11695-018-3609-x
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

843-850

Références

Obes Surg. 2014 Feb;24(2):232-40
pubmed: 23949905
Am J Clin Nutr. 1988 Jan;47(1):7-14
pubmed: 3337041
Front Psychol. 2015 Jul 14;6:966
pubmed: 26236255
Curr Obes Rep. 2016 Jun;5(2):291-7
pubmed: 27099165
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2985-3023
pubmed: 24239920
Obes Surg. 2016 Sep;26(9):2248-2254
pubmed: 27444806
Obes Rev. 2017 Jul;18(7):715-723
pubmed: 28489290
Med Clin North Am. 2018 Jan;102(1):183-197
pubmed: 29156185
Dig Dis Sci. 2017 Jun;62(6):1399-1408
pubmed: 28421456
Obes Surg. 2010 Aug;20(8):1128-32
pubmed: 19015930
J Endocrinol Invest. 2009 Feb;32(2):165-8
pubmed: 19411817
Cardiovasc Diabetol. 2013 May 16;12:76
pubmed: 23680280
Obes Surg. 2017 Oct;27(10):2546-2551
pubmed: 28451930
Surg Obes Relat Dis. 2016 Feb;12(2):420-9
pubmed: 26968503
GE Port J Gastroenterol. 2018 Sep;25(5):236-242
pubmed: 30320162
Surg Obes Relat Dis. 2016 Mar-Apr;12(3):462-467
pubmed: 27056407
N Engl J Med. 2017 Jul 6;377(1):13-27
pubmed: 28604169
Circulation. 2012 Mar 6;125(9):1157-70
pubmed: 22392863
Obesity (Silver Spring). 2011 May;19(5):1083-9
pubmed: 21372804
Am J Clin Nutr. 1989 Aug;50(2):255-60
pubmed: 2756912
Health Qual Life Outcomes. 2017 Oct 24;15(1):211
pubmed: 29065923
Obes Surg. 2018 Jun;28(6):1806-1808
pubmed: 29623590
Obes Facts. 2015;8(6):402-24
pubmed: 26641646
World J Gastroenterol. 2016 Jun 28;22(24):5495-504
pubmed: 27350727
Obes Surg. 2013 Dec;23(12):2068-74
pubmed: 23832520
Fertil Steril. 2017 Apr;107(4):833-839
pubmed: 28292617
Lancet. 2014 Aug 30;384(9945):766-81
pubmed: 24880830
Surg Obes Relat Dis. 2014 Mar-Apr;10(2):307-11
pubmed: 24462306
Wideochir Inne Tech Maloinwazyjne. 2015 Sep;10(3):445-9
pubmed: 26649094
Med Clin North Am. 2018 Jan;102(1):13-33
pubmed: 29156181
Clin Nutr. 2004 Oct;23(5):1226-43
pubmed: 15380917
Endocr Pract. 2016 Jul;22(7):842-84
pubmed: 27472012
Int J Obes (Lond). 2017 Mar;41(3):427-433
pubmed: 28017964
Am J Clin Nutr. 1982 Nov;36(5):936-42
pubmed: 7137077
J Transl Med. 2015 Jul 29;13:246
pubmed: 26219459
Am J Cardiol. 2014 Jul 15;114(2):320-3
pubmed: 24878123
Am J Epidemiol. 2014 Aug 1;180(3):254-62
pubmed: 24966215
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
pubmed: 11234459
Surg Laparosc Endosc Percutan Tech. 2017 Aug;27(4):e83-e86
pubmed: 28731953
Surg Endosc. 2016 Feb;30(2):424-429
pubmed: 25899814
Obes Surg. 2018 Dec;28(12):3733-3737
pubmed: 30173286
Clin Obes. 2013 Dec;3(6):172-9
pubmed: 25586733

Auteurs

Marcella Rodrigues Guedes (MR)

Gastroenterology Endogastro Rio Clinic, 43/1101, Siqueira Campos Street, Rio de Janeiro, RJ, 22031-901, Brazil.
Post Graduation Program in Clinical and Experimental Pathophysiology, Rio de Janeiro State University, Rio de Janeiro, Brazil.

Ricardo José Fittipaldi-Fernandez (RJ)

Gastroenterology Endogastro Rio Clinic, 43/1101, Siqueira Campos Street, Rio de Janeiro, RJ, 22031-901, Brazil. ricfittipaldi@hotmail.com.

Cristina Fajardo Diestel (CF)

Department of Applied Nutrition, Nutrition Institute, Rio de Janeiro State University, 12th floor/524, São Francisco Xavier Street, Rio de Janeiro, RJ, 20550-900, Brazil.

Márcia Regina Simas Torres Klein (MRST)

Department of Applied Nutrition, Nutrition Institute, Rio de Janeiro State University, 12th floor/524, São Francisco Xavier Street, Rio de Janeiro, RJ, 20550-900, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH